Techulon wins $1.9M DARPA contract to develop superbug treatment

05/10/2013 | Genetic Engineering & Biotechnology News

Techulon landed a Phase II, $1.9 million contract with the U.S. Defense Advanced Research Projects Agency to further develop its therapeutic program for multidrug-resistant bacteria, or superbugs. The firm plans to use the money to take a nanotherapeutic agent toward clinical trials.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX